Gifting allows recipients to access the article for free. Charles River Laboratories, a Wilmington, Mass., pharma services ...

Charles River has been riding rough waters in 2024, and as the CRO’s CEO predicted, the third quarter proved no exception. | ...

Charles River Laboratories raised its full-year profit forecast after beating analysts' estimates for quarterly results as the contract research firm expects demand to stabilize from biotech clients ...

CLSA upgraded Charles River (CRL) to Hold from Underperform with a $205 price target Published first on TheFly – the ultimate source ...

WILMINGTON, Mass. — WILMINGTON, Mass. — Charles River Laboratories International Inc. (CRL) on Wednesday reported third-quarter earnings of $69.7 million. On a per-share basis, the Wilmington, ...

Charles River Labs Q3 revenue of $1.01 billion surpassed expectations; however, revenue declined 1.6% YoY, and operating ...

Have you evaluated the performance of Charles River Laboratories' (CRL) international operations for the quarter ending September 2024? Given the extensive global presence of this medical research ...

Charles River Labs (CRL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tejas Savant from Morgan Stanley maintained a Hold rating on the ...

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2024. For the quarter, revenue was $1.01 billion ...